| Ident. | Authors (with country if any) | Title |
|---|
| 001800 |
Luis G. Paz-Ares [Espagne] ; Carlos Gomez-Roca [France] ; Jean-Pierre Delord [France] ; Andres Cervantes [Espagne] ; Ben Markman [Espagne, Australie] ; Jesus Corral [Espagne] ; Jean-Charles Soria [France] ; Yann Berge [France] ; Desamparados Roda [Espagne] ; Fiona Russell-Yarde [Royaume-Uni] ; Simon Hollingsworth [Royaume-Uni] ; José Baselga [Espagne] ; Pablo Umana [Suisse] ; Luigi Manenti [Suisse] ; Josep Tabernero [Espagne] | Phase I Pharmacokinetic and Pharmacodynamic Dose-Escalation Study of RG7160 (GA201), the First Glycoengineered Monoclonal Antibody Against the Epidermal Growth Factor Receptor, in Patients With Advanced Solid Tumors |
| 003076 |
Aude Echalier [Royaume-Uni, France] ; Karima Bettayeb [France] ; Yoan Ferandin [France] ; Olivier Lozach [France] ; Monique Clement [France] ; Annie Valette [France] ; Francois Liger [France] ; Bernard Marquet [France] ; Jonathan C. Morris [Australie] ; Jane A. Endicott [Royaume-Uni] ; Benoit Joseph [France] ; Laurent Meijer [France] | Meriolins (3-(Pyrimidin-4-yl)-7-azaindoles) : Synthesis, Kinase Inhibitory Activity, Cellular Effects, and Structure of a CDK2/Cyclin A/Meriolin Complex |
| 003956 |
F. Pein [France] ; R. Pinkerton [Australie] ; P. Berthaud [Suisse] ; K. Pritchard-Jones [États-Unis] ; G. Dick [États-Unis] ; G. Vassal [France] | Dose finding study of oral PSC 833 combined with weekly intravenous etoposide in children with relapsed or refractory solid tumours |
| 004F38 |
Patricia M. Lorusso [Australie] ; Roy S. Herbst [Australie] ; Danny Rischin [Australie] ; Malcolm Ranson [Royaume-Uni] ; Hilary Calvert [Royaume-Uni] ; Eric Raymond [France] ; Dirk Kieback [Pays-Bas] ; Stan Kaye [Royaume-Uni] ; Luca Gianni [Italie] ; Adrian Harris [Royaume-Uni] ; Thomas Bjork [Suède] ; Anne-Marie Maddox [États-Unis] ; Mace L. Rothenberg [États-Unis] ; Eric J. Small [États-Unis] ; Eric H. Rubin [États-Unis] ; Andrea Feyereislova [Royaume-Uni] ; Anne Heyes [Royaume-Uni] ; Steven D. Averbuch [États-Unis] ; Judith Ochs [États-Unis] ; José Baselga [Espagne] | Improvements in quality of life and disease-related symptoms in Phase I trials of the selective oral epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 in non-small cell Lung Cancer and other solid tumors |
| 005098 |
P. L. R. Mitchell [Australie] ; R. Basser [Australie] ; M. Chipman [Australie] ; A. Grigg [Australie] ; J. Cebon [Australie] ; I. D. Davis [Australie] ; J. Zalcberg [Australie] ; S. Ng [Australie] ; F. Appia [Australie, France] ; M. Green [Australie] | A phase I dose-escalation study of docetaxel with granulocyte colony-stimulating factor support in patients with solid tumours |
| 005294 |
J. Baselga [Espagne, Australie, États-Unis, Royaume-Uni, France, Pays-Bas, Italie, Suède] ; D. Rischin ; M. Ranson ; H. Calvert ; E. Raymond ; D. G. Kieback ; S. B. Kaye ; L. Gianni ; A. Harris ; T. Bjork ; S. D. Averbuch ; A. Feyereislova ; H. Swaisland ; F. Rojo ; J. Albanell | Phase I safety, pharmacokinetic, and pharmacodynamic trial of ZD1839, a selective oral epidermal growth factor receptor tyrosine kinase inhibitor, in patients with five selected solid tumor types |
| 006665 |
P. Baille [France] ; R. Bruno [France] ; J. H. M. Schellens [Pays-Bas] ; L. K. Webster [Australie] ; M. Millward [Australie] ; J. Verweij [Pays-Bas] ; G. Montay [France] | Optimal sampling strategies for bayesian estimation of docetaxel (taxotere) clearance |
